Stockport left the Places for Everyone plan in 2020 and now it looks like another borough in Oldham could follow ...

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

A council has narrowly voted to withdraw from a controversial housing scheme for more than 10,000 new homes after months of ...

Pfizer (NYSE:PFE) reported positive results from a Phase 3 study of its drug Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. The study, called TALAPRO-3, ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Rare earths prices were torpedoed by Chinese production tactics, but the Aussie government could be adapting to the new rules ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

At an extraordinary council session, members last night narrowly voted to pull out of the Greater Manchester spatial framework, reaffirming the weight of opinion from its November council meeting.